AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03502889 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPANK Block (Sensory Posterior Articular Nerves of the Knee)
Description: Injection of local anesthetic into the tissues on the posterior aspect of the knee to provide sensory blockade of the articular nerves of the knee.
Study NCT03502889 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor Canal Block
Description: Injection of local anesthetic into the inner thigh under ultrasound guidance to provide sensory blockade to the anterior aspect of the knee
Study NCT03502889 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block
Description: Injection of local anesthetic into the inner thigh under ultrasound guidance to provide sensory blockade to the anterior aspect of the knee
Study NCT03502889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine Hcl 0.5% Inj Vil 30Ml
Description: Amide local anesthetic, this concentration is commonly used to achieve surgical level anesthesia. The drug itself is not being studied and the same concentration will be used in all participants.
Study NCT03502889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine Hcl 0.5% Inj Vil 30Ml
Description: Amide local anesthetic, this concentration is commonly used to achieve surgical level anesthesia. The drug itself is not being studied and the same concentration will be used in all participants.
Study NCT03502889 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pajunk sonoplex stim needle
Description: Echogenic needle used for ultrasound guided nerve blockade.
Study NCT03502889 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pajunk sonoplex stim needle
Description: Echogenic needle used for ultrasound guided nerve blockade.
Study NCT01505933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Administer dexmedetomidine at 1mcg/kg over 10min followed by an infusion of dexmedetomidine at 1mcg/kg/hr and image the upper airway.~After the initial set of images is obtained, the depth of anesthesia will be increased by administering a bolus dose of dexmedetomidine 2mcg/kg followed by increase in the infusion rate to 3mcg/kg/hr. Upper airway images will be repeated 5mins after increasing infusion Image acquisitions will be repeated approximately 5 min after the increase in infusion rate.
Study NCT01505933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Administer propofol bolus at 2mg/kg,followed by an infusion of propofol at 100 mcg/kg/min. Upper airway images will be obtained 5 mins after the patient is stable on this infusion.~After the initial set of images is obtained, the depth of anesthesia will be increased by administering a bolus dose of 1mg/kg propofol and infusion increased to 240mcg/kg/min.~Image acquisitions will be repeated approximately 5 min after the increase in infusion rate.
Study NCT00117312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: One dose (2 x 2 mL) of degarelix 40 mg (10 mg/mL), subcutaneous injection.
Study NCT00117312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: One dose (2 x 2 mL) of degarelix 80 mg (20 mg/mL), subcutaneous injection.
Study NCT00117312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: One dose (2 x 2 mL) of degarelix 120 mg (30 mg/mL), subcutaneous injection.
Study NCT00117312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: One dose (2 x 2 mL) of degarelix 160 mg (40 mg/mL), subcutaneous injection.
Study NCT01167608 — intervention group
Intervention type: OTHER
Intervention: No Intervention. This is a cross-sectional survey study.
Description: No intervention.
Study NCT01409889 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Prevention Program
Study NCT01409889 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living Program
Study NCT03944837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen gas
Description: Transient maternal oxygen administration during echocardiographic and MRI imaging
Study NCT03338946 — intervention group
Intervention type: DEVICE
Intervention: CIED interrogation
Description: CareLink Express interrogation
Study NCT01243931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCT-guided laser phototherapeutic keratectomy
Description: Preoperative measurements from the OCT are used to assist the calculation in deciding the laser depth settings for removal of anterior corneal opacities and defects in the phototherapeutic PTK procedure. The surgeon uses the OCT data to plan a range of treatment parameters to remove most of the opacity while preserving at least 250 microns of residual corneal stroma.
Study NCT00515125 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dietary Advice
Description: Dietary Advice sheet
Study NCT00515125 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Oral Nutritional Supplements (Fortisip)
Description: These products are classified as non-medicinal, borderline substances, foods for special medical purposes.~A range of commercially available liquid oral nutritional supplements (Fortisip) will be offered daily for a 12 week period.
Study NCT03832361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMGN853
Description: IMGN853 6 mg/kg intravenously every 3 weeks until disease progression
Study NCT04131621 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab/Ipilimumab
Description: Immune checkpoint inhibitor combination
Study NCT03401749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate 2% Wipe
Description: Patients will be instructed to use CHG wipes after showering the night before surgery and again on the morning of surgery.
Study NCT03401749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theraworx Bath Wipes
Description: Theraworx TM is a cosmetic product that is a non-rinse skin formulation that combines multiple ingredients, including Aloe Concentrate, Allantoin, Tego Betaine F 50, Tego Betaine L-7, Lauryl Glucoside, Abil 8852, Vitamin E, Natural Fragrances, Methyl paraben, Propyl paraben, EDTA, Antimicrobial Preservative, Colloidal Silver, and Beta Glucan, in preoperative disposable bath wipes. The main proposed antimicrobial mechanism of action involves the local reduction in skin pH to around 4.6.
Study NCT03619915 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry
Description: The test will follow the norms of the American Thoracic Society and reference values relative to the Brazilian population. The tests will be performed by physical therapists using the One Flow FVC® portable spirometer (Clement Clarke, England) and met the criteria for acceptance and reproduction of manoeuvres
Study NCT02815956 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02845492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qigong
Description: Qigong is a mind-body exercise based around gentle exercise and the cultivation of a meditative focus on bodily sensations
Study NCT02845492 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complete Health Improvement Program (CHIP)
Description: The CHIP program is a validated weekly wellness and exercise program designed to promote health and wellbeing.
Study NCT00838630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg tablets
Description: 1 x 100 mg
Study NCT00838630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pletal® 100 mg tablets
Description: 1 x 100 mg
Study NCT04377386 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1000 IU D vitamin
Description: Participants in the intervention group will receive 105 DV doses of 1000 IU. The supplementation will be given by the Farma de Colombia laboratory, known commercially as Farma D, whose presentation is in soft gelatin capsules. It is recommended to take one dose per day at the same time and participants should record the daily intake time of the supplement for 15 weeks on a calendar.
Study NCT03876054 — intervention group
Intervention type: DEVICE
Intervention: Spinal cord stimulation (SCS)
Description: Subjects will be implanted with market-released Abbott SCS systems
Study NCT03619915 — intervention group
Intervention type: OTHER
Intervention: Functional Independence Measure
Description: Will be used to evaluate the functional independence of patients containing eighteen items encompassing six dimensions. Each item can receive scores of one to seven, where one corresponds to total dependency and seven to full independence. Each dimension is analysed by the sum of the items that compose it and the total score is given by the sum of each dimension, being able to vary from 18: complete dependence; 19 to 60: greater dependence (assistance of up to 50% of tasks); 61 to 103: less dependency (assistance of up to 25% of tasks); and 104 to 126: independent.
Study NCT03876054 — intervention group
Intervention type: DEVICE
Intervention: Dorsal root ganglion stimulation (DRG)
Description: Subjects will be implanted with market-released Abbott DRG system
Study NCT03417960 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS
Description: The investigators will treat post-partum depressed subjects with accelerated intermittent theta burst stimulation. iTBS will be delivered via a MagVenture MagPro100 and Cool-B65 coil. The investigators will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Treatment will be delivered at 120% of the motor threshold.~In study 1, the accelerated paradigm will consist of 10 such sessions separated by 15 minutes, for three treatment days per week. There will be 2 weeks of 10 sessions on each of three days for a total of six treatment days, divided by one treatment-free week between treatment weeks. In study 2, the accelerated paradigm will consist of 12 sessions per day for 5 total treatment days. Treatments will be delivered at the 10-20 EEG coordinate for F3 (approximating the left DLPFC), and will be found using the Beam-F3 method.
Study NCT01844050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine
Description: According to the traditional Chinese medicine syndrome of subject to make up a prescription within the 35 kinds of chosen Chinese herbal medicine, and the dosage without limitation.
Study NCT01844050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03574558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD-Logic Switch Advisor
Description: Study algorithm will be used in order to determine the initial pump setting/ MDI dosing while switching from from MDI to pump therapy or vice versa
Study NCT03891784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO
Study NCT00829673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmethylphenidate Hydrochloride
Description: 10 mg Tablet
Study NCT00829673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmethylphenidate Hydrochloride
Description: 10 mg Tablet
Study NCT06560710 — intervention group
Intervention type: OTHER
Intervention: vitrectimy
Description: Clinical characteristics and surgical outcomes
Study NCT02348463 — intervention group
Intervention type: DRUG
Intervention: Clindamycin-2-phosphate
Description: how many women will deliver before the 37th week of gestation
Study NCT00561015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Telaprevir 750 mg tablet will be administered three times a day orally for 2 weeks.
Study NCT03990350 — intervention group
Intervention type: OTHER
Intervention: 24-hour dietary recall diary
Description: At the initial encounter the co-investigator Dr. David Garcia, who is a certified Spanish translator will complete the 24-hour dietary recall diary with the subject and parent.
Study NCT02585128 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Delirium assessment
Description: During the first post-procedural five days all patients will be evaluated on a daily basis for delirium occurrence by the CAM (Confusion Assessment Method) or CAM - ICU (Confusion Assessment Method - Intensive Care Unit)
Study NCT02585128 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MMSE (Mini Mental State Examination)
Study NCT02585128 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Barthel index
Study NCT02585128 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: HADS (Hospital Anxiety and Depression Scale)
Study NCT02585128 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MNA-SF (Mini Nutritional Assessment - Short Form)
Study NCT02585128 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NIRS (Near-Infrared Spectroscopy)
Description: Regional cerebral oxygen saturation monitoring during TAVI procedure
Study NCT02585128 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CIRS (Cumulative Illness Rating Scale)
Study NCT02862275 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT02862275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04377386 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 200 IU D vitamin
Description: Participants in the control group will receive 105 DV doses of 200 IU. The supplementation will be given by the same laboratory; it will have the same characteristics and recommendations for the intake as for the intervention group.
Study NCT03170921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Angola
Description: The rhythm performance (Angola) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
Study NCT03170921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Benguela
Description: The rhythm performance (Benguela) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
Study NCT03170921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: São Bento
Description: The rhythm performance (São Bento) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
Study NCT02804646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human endostatin
Description: endostar was continuous intravenous transfusion for 7 days，with the dose of 15mg/m2 for one day
Study NCT02804646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed plus cisplatin or carboplatin
Description: the dose of pemetrexed was 500mg/m2 on day 1 of every 21 days,plus cisplatin or carboplatin.
Study NCT02804646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed plus cisplatin or carboplatin
Description: the dose of pemetrexed was 500mg/m2 on day 1 of every 21 days,plus cisplatin or carboplatin.
Study NCT01294072 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curcumin
Description: tablets-3.6 gram (gm) taken daily for 7 days - 15 subjects
Study NCT01294072 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin conjugated with plant exosomes
Description: tablets-taken daily for 7 days - 15 subjects
Study NCT04084392 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bridge Clinic
Description: Referral to the Bridge Clinic for temporary outpatient addiction treatment while the bridge clinic identifies an outpatient addiction treatment provider to accept the patient for long term treatment.
Study NCT04084392 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Referral to an outpatient provider for addiction treatment.
Study NCT00509106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil for Injection
Description: 2 consecutive, 300 mg dose parenteral infused over 30 minutes, every 12 hours for 5 to 7 days
Study NCT00509106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: 1 g dose parenteral infused over 30 minutes, every 24 hours for 5 to 7 days
Study NCT00509106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind
Study NCT04318574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance, Agility, Strengthening Exercise (BASE) Class
Description: The BASE class will be conducted twice weekly for 1.5 hours each session over a 6-week period and will include a 10-minute warm-up, 30 minutes of static and dynamic balance exercises, 20 minutes of lower extremity strengthening exercises, and a 10-minute cool-down. There will be weekly falls prevention and mobility enhancement education provided during the class.
Study NCT03542188 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Primary Stroke Center (PSC)
Description: Transport to a primary stroke center for early IV-thrombolysis followed by a secondary transport to a comprehensive stroke center for EVT if needed.
Study NCT03542188 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Stroke Center (CSC)
Description: Direct transport to a comprehensive stroke center for IV-thrombolysis and early EVT.
Study NCT03542188 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive Stroke Center (CSC)
Description: Direct transport to a comprehensive stroke center for IV-thrombolysis and early EVT.
Study NCT04438421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filming mouthwash formulation, enriched with Hydrogen Peroxide and Hyaluronic Acid
Description: Subjects will then be given the test product, BMG0703, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
Study NCT00561015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-IFN-alfa-2a + Ribavirin (Standard Treatment)
Description: Standard treatment of Peg-IFN-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (400 mg as oral tablet twice daily) will be administered from Day 15 to Week 24 or 26 in the T2 \& PR24 - genotype 2 and 3 group and from Day 1 to Week 24 or 26 in the T2/PR24 - genotype 2 and 3 group.
Study NCT00561015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFN-alfa-2a + Ribavirin (Standard Treatment)
Description: Standard treatment of Peg-IFN-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (400 mg as oral tablet twice daily) will be administered from Day 15 to Week 24 or 26 in the T2 \& PR24 - genotype 2 and 3 group and from Day 1 to Week 24 or 26 in the T2/PR24 - genotype 2 and 3 group.
Study NCT00561015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet to telaprevir will be administered three times a day orally for 2 weeks.
Study NCT00492076 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pangramin Plus D. pteronyssinus 100%
Description: 1. Active. Pangramin Plus D. pteronyssinus 100%~2. Placebo. Pangramin Plus placebo
Study NCT00492076 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pangramin Plus D. pteronyssinus 100%
Description: 1. Active. Pangramin Plus D. pteronyssinus 100%~2. Placebo. Pangramin Plus placebo
Study NCT04343196 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Diagnostic Angiography (DSA or DVA based on randomization result)
Description: After radial/brachial/femoral artery puncture using Seldinger technique, the investigators first position a pigtail catheter above the level of the renal arteries. With Siemens Artis Zee Pure DSA machine the examiner will use a postero-anterior X-ray view for the first image, which is an aortography of some part of the iliac system. Then, the catheter will be repositioned to the aortic bifurcation and 15-18 mL contrast media (CM) with 9-10 mL/s flow for the ilio-femoral region will be injected. All of the following image series will be made from this catheter position, with a 9 mL/s flow rate. In cases for when the recorded image series will be inconclusive, image series with left/right oblique position will be recorded. All femoro-popliteal images will be recorded with 10-16 ml CM and crural regions with 12-22mml. DSA images will be calculated from all series on a dedicated Syngo workstation and used for diagnosis. DVA images will be calculated by the Kinepict Medical Imaging Tool